share_log

Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts

リジェネロンファーマシューティカルズの評価:16人の金融アナリストからの洞察

Benzinga ·  05/03 12:00

Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 16 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings47410
Last 30D00100
1M Ago31210
2M Ago13000
3M Ago03100

The 12-month price targets, analyzed by analysts, offer insights with an average target of $1046.81, a high estimate of $1189.00, and a low estimate of $720.00. This current average has increased by 1.92% from the previous average price target of $1027.10.

price target chart

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent analyst actions sheds light on...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする